RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Circassia Pharma, an Oxford UK respiratory disease company, entered a $32.7 million agreement to acquire US and China marketing rights for AirNOvent, a nitric oxide product developed by US-based AIT Therapeutics. AirNOvent is a ventilator compatible nitric oxide product that is administered for respiratory failure associated with persistent pulmonary hypertension of newborns (PPHN). AIT, which also intends to seeks a second indication for AirNOvent, expects to apply for US approval of the product in Q2 2019, with market launch in 2020.
Source: China Biotoday
